News

These conditions often result in organ failure due to myofibroblast activation, scarring, and tissue inflammation. Ono will work alongside Mediar to utilise its fibrosis-focused discovery platform, expertise in

The post Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments appeared first on Pharmaceutical Business review.

This collaboration will focus on utilising Evotec’s data-driven discovery platform alongside its AI data science and advanced screening technologies. It aims to accelerate the discovery and validation of

The post Evotec and Odyssey collaborate on AI-enabled R&D appeared first on Pharmaceutical Business review.

The agreement involves access to ALT-B4 (berahyaluronidase alfa), a recombinant human hyaluronidase created with Alteogen’s Hybrozyme platform. This technology is intended to convert biologics typically given via intravenous

The post Alteogen signs $365m Hybrozyme licensing deal with pharma company appeared first on Pharmaceutical Business review.

This initiative builds on an established partnership between the two companies, under which BMS already utilises Schrödinger’s computational platform for drug discovery projects. The new arrangement will extend

The post Schrödinger and BMS expand partnership to deploy AI for drug discovery appeared first on Pharmaceutical Business review.

The funds will be used for AsymBio’s principal business operations and drive further expansion of its manufacturing capacity. Asymchem Group will contribute 1.05bn yuan while Hillhouse Qirui will

The post AsymBio to secure $184m to support growth in biologics manufacturing appeared first on Pharmaceutical Business review.

The move aims to address challenges in the sector where analytical work behind research decisions is often slow and dispersed, pushing scientists to use multiple disconnected tools and

The post Phylo and Chugai collaborate to deploy AI platform in drug discovery appeared first on Pharmaceutical Business review.

The designation is specifically for patients whose tumours demonstrate a KRAS G12C mutation confirmed by an FDA-approved test and covers olomorasib administered as a monotherapy. Olomorasib (LY3537982) is

The post FDA grants breakthrough therapy designation to Lilly’s olomorasib appeared first on Pharmaceutical Business review.

The deal will take the Nasdaq-listed Lantheus private. Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per share upon closing. Lantheus’ shareholders

The post Curium to acquire Lantheus in all-cash deal worth up to $8bn appeared first on Pharmaceutical Business review.

The agreement covers the use of senaparib as a maintenance monotherapy for adult patients with advanced epithelial high-grade ovarian, fallopian tube, and primary peritoneal cancer. Under the agreement,

The post IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib appeared first on Pharmaceutical Business review.

The company said existing investors Duquesne Family Office and Bristol Myers Squibb participated in the round, joined by new investors Catalio Capital Management, Eli Lilly and Company, and

The post Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy appeared first on Pharmaceutical Business review.